UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants with Bronchiolitis

International journal of immunopathology and pharmacology, 2012-04, Vol.25 (2), p.485-491

2012

Volltextzugriff (PDF)

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

European urology, 2019-12, Vol.76 (6), p.782-789

2019

Volltextzugriff (PDF)

Placemaking and Cultural Landscapes

1, 2023

Volltextzugriff (PDF)

Organ preservation in muscle-invasive urothelial bladder cancer

Current opinion in oncology, 2024-05, Vol.36 (3), p.155

2024

Volltextzugriff (PDF)

Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Urologic oncology, 2021-11, Vol.39 (11), p.787.e17-787.e21

2021

Volltextzugriff (PDF)

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4600-4600

2023

Volltextzugriff (PDF)

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4571-4571

2023

Volltextzugriff (PDF)

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16573-e16573

2023

Volltextzugriff (PDF)

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4607-TPS4607

2023

Volltextzugriff (PDF)

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16506-e16506

2023

Volltextzugriff (PDF)

The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.452-452

2022

Volltextzugriff (PDF)

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.3-3

2021

Volltextzugriff (PDF)

664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors

Annals of oncology, 2021-09, Vol.32, p.S690-S690

2021

Volltextzugriff (PDF)

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4599-TPS4599

2021

Volltextzugriff (PDF)

A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.452-452

2021

Volltextzugriff (PDF)

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5039-5039

2020

Volltextzugriff (PDF)

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5037-5037

2020

Volltextzugriff (PDF)

Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-326

2022

Volltextzugriff (PDF)

Obesity and the metabolic syndrome in a student cohort from Southern Italy

Nutrition, metabolism, and cardiovascular diseases, 2009-11, Vol.19 (9), p.620-625

2009

Volltextzugriff (PDF)

Clinical value of 18 FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Urologic oncology, 2021-11, Vol.39 (11), p.787.e17

2021

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(90)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(16)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Female
(9)
Male
(8)
Cultural Landscape
(6)
Oncology
(6)
Placemaking
(6)
Sustainability
(6)
Adult
(5)
Aged
(5)
Carcinoma, Transitional Cell - Drug Therapy
(4)
Middle Aged
(4)
Bladder Cancer
(3)
Cardiovascular System & Cardiology
(3)
Culture
(3)
Urinary Bladder Neoplasms - Drug Therapy
(3)
Urothelial Cancer
(3)
Young Adult
(3)
Adolescent
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants with Bronchiolitis

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Placemaking and Cultural Landscapes

Organ preservation in muscle-invasive urothelial bladder cancer

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab

The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi)

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors

664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies

Cabozantinib Plus Nivolumab Phase I Expansion Study in Metastatic Urothelial Carcinoma Patients Refractory to Immune Checkpoint Inhibitor Therapy

A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma

Circulating Tumor Cell Subtypes and T-cell Population as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi)

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy

Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers

Obesity and the metabolic syndrome in a student cohort from Southern Italy

Clinical value of 18 FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Suchergebnisse filtern